Personalis expands Medicare coverage for cancer test to pre-surgery monitoring
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring
May 20, 2026 6:00 AM EDTExpanded coverage enables Medicare beneficiaries with Stage II-III TNBC or HER2+ breast cancer to access ultrasensitive MRD testing to monitor response to neoadjuvant therapy
FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Centers for Medicare & Medicaid Services (CMS) Molecular Diagnostic Services Program (MolDX) has expanded coverage for the companys NeXT Personal minimal residual disease (MRD) test. The new coverage determination is for monitoring treatment response to neoadjuvant therapy (NAT) in patients diagnosed with Stage II-III... More
